Amphorna Biosciences is developing a next-generation targeted RNA medicines platform that combines proprietary delivery, advanced RNA design, and precise cell targeting to create breakthrough therapies for fibrosis, oncology, and immunology, including a first-in-class AOC strategy.
RNA medicines can be designed to address a broad range of therapeutic areas, including fibrosis, oncology, immunology, and other major diseases.
Fibrosis-targeted LNPs and AOC approaches are engineered to reach disease-relevant cells in extrahepatic tissues beyond the liver.
A proprietary platform for oncology and immunology, designed to deliver multiple RNA therapeutics against challenging targets and complex biology.
Leave your name and email to receive the latest news, research progress, and technology updates from Amphorna.